Addex Therapeutics Ltd (FRA:APE)

Market Cap	5.67M -10.9%
Revenue (ttm)	118.39K -55.5%
Net Income	-7.53M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0370
Previous Close	0.0430
Day's Range	0.0370 - 0.0370
52-Week Range	0.0310 - 0.0810
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 15, 2026

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, ad...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 3
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: APE

Financial Performance

Financial numbers in CHF

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 26, 2026

Data Sources Report a data error